



- (51) **International Patent Classification:**
C07K 14/605 (2006.01) *A61K 38/26* (2006.01)
- (21) **International Application Number:**
PCT/US2024/045369
- (22) **International Filing Date:**
05 September 2024 (05.09.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/CN2023/117248
06 September 2023 (06.09.2023) CN
- (71) **Applicant:** **AMBio, INC.** [US/US]; 442 Park West Dr.,
Grovetown, Georgia 30813 (US).
- (72) **Inventors:** **BAI, Juncai**; 12204 Cattail Dr. West, Jack-
sonville, Florida 32223 (US). **ZHANG, Guoqing**; Room
604, Building 4, No. 177 Qiheng Road, Pudong, Shang-

hai 200125 (CN). **ZHANG, Fuliang**; Room 2301, Build-
ing 16, No. 821 East Wuwei Road, Putuo, Shanghai 200331
(CN). **PENNINGTON, Michael**; 42 Mayapple Dr., Sap-
phire, North Carolina 28774 (US). **SINGH, Simrat**; 903
Cranbrook Way, Evans, Georgia 30809 (US).

(74) **Agent:** **KOZAKIEWICZ, Cynthia** et al.; Cooley LLP,
1299 Pennsylvania Ave., NW, Suite 700, Washington, Dis-
trict of Columbia 20004 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) **Title:** STABLE GLP-1 ANALOGS FOR THE TREATMENT OF HUMAN DISEASE AND DISORDERS




FIG. 1

(57) **Abstract:** The disclosure described herein provides for enzymatically stable and potent GLP-1 analogs (i.e., derivatives) for the treatment of metabolic disease or disorder in a subject. In some embodiments, the GLP-1 analog is a derivatized GLP-1 peptide, wherein the derivatized peptide has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid differences from any one of GLP-1, GLP-1(7-39), GLP-1(7-36), GLP-1(7-37). In certain embodiments, the GLP-1 analog comprises at least one lysine substituent. The GLP-1 analogs described herein demonstrate potent receptor binding and extended plasma half-life. A pharmaceutical composition of the GLP-1 analogs is described herein for the treatment of metabolic disease or disorder in a subject, such as diabetes or obesity.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*